Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
about
Effects of Specialty Pharmacy Care on Health Outcomes in Multiple SclerosisPrescriber utilization of dalfampridine extended release tablets in multiple sclerosis: a retrospective pharmacy and medical claims analysis.Cost-effectiveness of disease-modifying therapy for multiple sclerosis: a population-based study.Preferred features of oral treatments and predictors of non-adherence: two web-based choice experiments in multiple sclerosis patients.Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.Meeting the needs of people with primary progressive multiple sclerosis, their families, and the health-care community.Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability.Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence.Burden of a multiple sclerosis relapse: the patient's perspective.Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom
P2860
Q33572798-EF3C9D38-03AF-4FA1-BEE4-1B758EBDF9A5Q34758029-73D36E4C-0871-4137-AAFD-FF0E43F92313Q35119597-FAABB760-6738-42BA-898E-923D1E9C5EFCQ35223204-297F0D7F-4F40-40EB-9020-30DD33BE8054Q36968664-7281A8AF-7016-4246-B965-FB002C1C5519Q37442084-3D03D250-9270-478D-BBE5-D767216DB664Q37884071-8E9D3488-5B34-4EE4-BCF3-7CB031A0A864Q37976344-2DF18402-D445-4D3A-B10A-869D333ABB60Q48503591-9610A900-5CFD-44E7-B2C4-F29C534930CBQ57573402-82042701-8A5A-4837-ACF2-54BC3D7DB26F
P2860
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@en
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@nl
type
label
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@en
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@nl
prefLabel
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@en
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@nl
P2093
P2860
P356
P1476
Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study.
@en
P2093
S Jureidini
Y Komatsuzaki
P2860
P304
P356
10.1177/1352458507086463
P577
2008-06-01T00:00:00Z